The Mölndal facility’s new section, opened on October 22, complements the part of the building inaugurated on August 24, which focuses on exercise, rehabilitation, and preventive health. Tenants include CCRM Nordic, the University of Gothenburg, Chalmers University of Technology, and the City of Mölndal. Approximately 2,300m² of office and lab space is still available for companies and research organizations in health and life science.

“CCRM Nordic’s expertise in cell and gene therapy complements the organizations already here and creates new opportunities for collaboration. Together, we are strengthening the conditions for promising research to be developed into treatments that reach patients,” says Britta Stenson, Director Ecosystem, Vectura.

The next step is establishing GMP operations, with manufacturing planned to start in 2027.

CCRM Nordic supports researchers and companies developing advanced therapy medicinal products (ATMPs), including cell and gene therapies, with the aim of strengthening Nordic collaboration in the field. Its development laboratory is already up and running, supporting the development and optimization of manufacturing processes and analytical methods. The next step is establishing GMP operations, with manufacturing planned to start in 2027.

“With these new facilities, we are taking an important step toward strengthening Sweden’s capacity to develop and manufacture advanced therapies. We are building an environment where innovative treatments can move from research to clinical application, with the goal of getting more therapies to patients,” says Fredrik Wessberg, CEO, CCRM Nordic.

Related article

Beyond manufacturing: Stockholm turns to multiomics to improve cell and gene therapies

Stockholm-Uppsala has built substantial clinical, research, and manufacturing capabilities around advanced therapies. Bringing those strengths closer to the region’s expertise in proteomics, genomics, and other molecular technologies could help answer the next questions in cell and gene therapy: why treatments work, why they fail, and how more patients can benefit.

The inauguration was marked by a symposium on the future of cell and gene therapy, organized by CCRM Nordic and Vectura. Speakers included Michael May, President and CEO of Canada’s CCRM, and Jeanette Edblad, Director of the Office for Life Sciences at the Government Offices in Sweden.